株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

カナダの医薬品市場

The Pharmaceutical Market: Canada

発行 Espicom Business Intelligence 商品コード 242141
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
カナダの医薬品市場 The Pharmaceutical Market: Canada
出版日: 2013年01月31日 ページ情報: 英文
概要

当レポートでは、カナダの医薬品市場について、市場全体の動向と法規制、 医薬品流通チャネルなどを分析し、OTC医薬品、ジェネリック医薬品、 バイオ医薬品・バイオシミラーなどのセグメント別の動向、市場の機会と課題などを併せ、 概略下記の構成でお届けいたします。

目次

エグゼクティブサマリー

  • スナップショット: Espicom の戦略的分析
  • スナップショット: 主要データ予測

マクロ環境

  • 政治環境
  • 経済環境
  • 法環境

    人口統計

疫学

  • 病気の負荷
  • 羅漢率

ヘルスケア - 保健統計付

  • 組織・機構
  • 医療費
  • インフラストラクチャー
  • サービス
  • 労働力

規制関連情報

  • 国内当局
  • 薬事規制
  • 市場登録
  • プロモーション

価格決定および償還

  • 価格決定
  • 償還

流通チャネル

  • 医薬品 卸売り
  • 医薬品 小売

市場分析

  • 規模
  • 製品開発
  • 製造
  • 貿易

競合状況

  • 事業者団体
  • 企業情報

OTC 医薬品

  • 市場規模
  • 競合状況

ジェネリック医薬品

  • 規制
  • 価格決定および償還
  • 市場規模
  • 競合状況

生物製剤/バイオシミラー

  • 規制
  • 製品開発
  • 競合状況

結び: 機会と課題

  • Espicom の戦略的分析
  • レーダー解析
  • SWOT分析

関係各機関・組織一覧

  • 企業情報
  • 流通業者
  • 政府組織
  • 薬局チェーン
  • 業界団体

図表


このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

Summary

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Description

THE PHARMACEUTICAL MARKET: CANADA - REVIEW

The stable economic and political environment in Canada will help pharmaceutical companies to generate a consistent market growth in Q412. However, drugmakers will continue to face pricing pressure from the government and patent cliff effects in the country. Nevertheless, the epidemiological demands of an ageing population will counterbalance some of those pressures, even though we expect the generic drug market will significantly outperform its patented counterpart.

Headline Expenditure Projections Pharmaceuticals: CAD26.28bn (US$26.57bn) in 2011 to CAD26.64bn (US$25.87bn) in 2012; +1.4% growth in local currency terms and -2.7% growth in US dollar terms. Forecast slightly up from Q312 on account of macroeconomic factors. Healthcare: CAD181.47bn (US$183.47bn) in 2011 to CAD190.54bn (US$184.99bn) in 2012; +5.0% growth in local currency terms and +0.8% growth in US dollar terms. Forecast up slightly from Q312 due to macroeconomic factors. Medical Devices: CAD6.52bn (US$6.59bn) in 2011 to CAD6.78bn (US$6.58bn) in 2012; +3.9% growth in local currency terms and -0.2% growth in US dollar terms. Forecast the same as in Q312. Risk/Reward Rating: In BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs) for Q412, Canada stays in second place in our regional matrix, which assesses 17 key markets in the Amercias. However, the average RRR score for the region decreased from 49.6 in Q312 to 49.2 in Q412 due to the worsening average industry rewards score.

Product Description

The Canadian Pharmaceuticals & Healthcare Report features Espicom's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

Espicom's Canadian Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Canadian pharmaceutical and healthcare industry.

Key Benefits

Benchmark Espicom's independent pharmaceutical and healthcare industry forecasts to test other views - a key input for successful budgeting and strategic business planning in the Canadian pharmaceutical and healthcare market.

Target business opportunities and risks in the pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Canada.

Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Espicom's forecast analysis, and taken together with Espicom's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Espicom Industry Forecasts

Forecasts to end-2016 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per '000 population), doctors (per '000 population), birth and mortality rate (per '000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

Table of Contents

Executive Summary

SWOT Analysis

  • Canada Pharmaceuticals And Healthcare Industry SWOT
  • Canada Political SWOT
  • Canada Economic SWOT

Pharmaceutical Risk/Reward Ratings

  • Table: Americas Pharmaceutical Risk/Reward Ratings, Q113
  • Rewards
  • Risks

Canada - Market Summary

Regulatory Regime

  • Pharmacovigilance
  • International Collaboration
  • Intellectual Property Regime
  • Pricing Regime
  • Reimbursement Regime
  • Recent Regulatory Developments

Industry Developments

  • Epidemiology
  • Non-Communicable Diseases
  • Healthcare Sector 46
  • Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
  • National Pharmaceuticals Strategy
  • Research & Development Sector
  • Biotechnology
  • Table: Biotechnology Products in Canadian Company Pipelines, 2011
  • Personalised Medicine
  • Medical Devices Industry

Industry Forecast Scenario

  • Overall Market Forecast
  • Table: Canada Pharmaceutical Sales, Historical Data and Forecasts

Key Growth Factors - Macroeconomic

  • Table: Canada Healthcare Expenditure Trends, Historical Data and Forecasts
  • Table: Canada Government Healthcare Expenditure Trends, Historical Data and Forecasts
  • Table: Canada Private Healthcare Expenditure Trends, Historical Data and Forecasts
  • Key Growth Factors - Macroeconomic
  • Table: Canada -GDP By Expenditure, Real Growth %
  • Prescription Drug Market Forecast
  • Table: Canada Prescription Drug Market Indicators, Historical Data and Forecasts
  • Patented Drug Market Forecast
  • Table: Canada Patented Drug Market Indicators, Historical Data and Forecasts
  • Generic Drug Market Forecast
  • Table: Canada Generics Drug Market Indicators, Historical Data and Forecasts
  • OTC Medicine Market Forecast
  • Table: Canada Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
  • Pharmaceutical Trade Forecast
  • Table: Canada Pharmaceutical Trade Data And Forecasts (US$mn)
  • Table: Canada Pharmaceutical Trade Data And Forecasts (CADmn)
  • Medical Device Market Forecast
  • Table: Canada Medical Device Market Indicators, Historical Data and Forecasts
  • Other Healthcare Data
  • Table: Health Expenditure by Sector & Type, 2009 (CADmn)
  • Table: Pharmacists by Type and Province & Territory, 2011
  • Table: Active Physicians, 2005-2009
  • Key Risks To Forecasts

Competitive Landscape

  • Pharmaceutical Industry
  • Table: Top-20 Pharmaceutical Companies According To Market Capitalisation On The Canadian Stock Exchange
  • Table: Members of Rx&D, 2011
  • Table: Active Members of Consumer Health Products Canada, 2011
  • Table: Members of CGPA, 2011
  • Pharmaceutical Reimport Policy
  • Recent Pharmaceutical Company Developments
  • Table: Cangene's Financial Results, 2005-2010 (CAD000s)
  • Table: Cangene's Financial Results for Biopharmaceutical Operations, 2007-2010 (CAD000s)
  • Pharmaceutical Retail
  • Table: Pharmacy Distributor Members of CAPDM, 2011
  • Table: Pharmacies by Type and Province &erritory, 2011
  • Table: Retail Members of CACDS, 2011
  • Table: Shoppers Drug Mart's Financial Highlights, 2009-2010 (CAD000s)

Company Profiles

  • Domestic Companies
    • Apotex
    • Valeant
  • Multinational Companies
    • Pfizer
    • GlaxoSmithKline
    • Sanofi
    • Merck & Co
    • Novartis

Demographic Outlook

  • Table: Population By Age Group, 1990-2020 ('000)
  • Table: Population By Age Group, 1990-2020 (% of total)
  • Table: Key Population Ratios, 1990-2020
  • Table: Rural/Urban Population Split, 1990-2020

Glossary

BMI Methodology

  • How We Generate Our Pharmaceutical Industry Forecasts
  • Pharmaceuticals Risk/Reward Ratings Methodology
  • Ratings Overview
  • Table: Pharmaceutical Business Environment Indicators
  • Weighting
  • Table: Weighting Of Components
  • Sources
Back to Top